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Combinations of gemcitabine and trabectedin exert modest synergistic cytotoxic effects
on two pancreatic cancer cell lines. Here, systems pharmacodynamic (PD) models
that integrate cellular response data and extend a prototype model framework were
developed to characterize dynamic changes in cell cycle phases of cancer cell
subpopulations in response to gemcitabine and trabectedin as single agents and in
combination. Extensive experimental data were obtained for two pancreatic cancer
cell lines (MiaPaCa-2 and BxPC-3), including cell proliferation rates over 0–120 h of
drug exposure, and the fraction of cells in different cell cycle phases or apoptosis. Cell
cycle analysis demonstrated that gemcitabine induced cell cycle arrest in S phase, and
trabectedin induced transient cell cycle arrest in S phase that progressed toG2/M phase.
Over time, cells in the control group accumulated in G0/G1 phase. Systems cell cycle
models were developed based on observed mechanisms and were used to characterize
both cell proliferation and cell numbers in the sub G1, G0/G1, S, and G2/M phases
in the control and drug-treated groups. The proposed mathematical models captured
well both single and joint effects of gemcitabine and trabectedin. Interaction parameters
were applied to quantify unexplainable drug-drug interaction effects on cell cycle arrest
in S phase and in inducing apoptosis. The developed models were able to identify and
quantify the different underlying interactions between gemcitabine and trabectedin, and
captured well our large datasets in the dimensions of time, drug concentrations, and
cellular subpopulations.
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INTRODUCTION
Pancreatic cancer is a highly aggressive malignancy and shows resistance to almost all
existing treatments (Oberstein and Olive, 2013). Gemcitabine (GEMZAR, Eli Lilly, Indianapolis,
IN), a standard therapy for the treatment of advanced pancreatic cancer, can disrupt DNA
replication and activate the S phase checkpoint (Yip-Schneider et al., 2001; Morgan et al., 2005;
Abbreviations: CCM, cell cycle model; DDI, drug-drug interaction; PK/PD, pharmacokinetics/pharmacodynamics.
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Robinson et al., 2006). However, the benefits of gemcitabine
monotherapy are limited, and combinations of other agents
with gemcitabine may improve survival of pancreatic cancer
patients. Trabectedin (YONDELIS R©, Et-743; Johnson and
Johnson Pharmaceutical Research and Development, Raritan,
NJ, USA; PharmaMar S.A.U., Madrid, Spain) is a promising
anticancer agent that has demonstrated clinical activity in many
drug-resistant cancer cell lines, and has been approved by the US
Food and Drug Administration for advanced soft tissue sarcoma.
It has three tetrahydroisoquinoline rings. The A and B subunits
bind covalently to the DNAminor groove and bend DNA toward
the major groove, and the C ring protrudes to interact with
adjacent macromolecules such as transcription factors (D’Incalci
and Galmarini, 2010). Trabectedin was found previously to cause
cell cycle arrest at S and G2/M phases in many human tumor
cell lines (Gajate et al., 2002; Simoens et al., 2003). Because
of its unique mechanisms of action (D’Incalci and Galmarini,
2010), trabectedin has been reported to exert anti-tumor activities
in many malignancies, including soft-tissue sarcomas, ovarian
carcinomas, and breast cancer (D’Incalci et al., 2002; D’Incalci
and Zambelli, 2015).
Our previous report provided indications from the literature
that gemcitabine and trabectedin have mechanisms that may
interrelate to produce synergism in their chemotherapeutic
effects and we demonstrated that the combination of gemcitabine
and trabectedin exerts synergistic cytotoxic effects on pancreatic
cancer cells (Miao et al., 2016a). Here we have extended the
work, assessing cell cycle subpopulations in two pancreatic cancer
cell lines to examine drug interactions, because asynchronous
cancer cell cultures are composed of different subpopulations,
and each may have different sensitivities to drugs. Previously we
also developed a pharmacodynamic (PD) model that was able
to characterize simultaneously 32 sets of data for single-agent
and combined drug effects on pancreatic cancer cell lines (Miao
et al., 2016a). Here we have expanded the model to integrate
additional data regarding the temporal changes of cell numbers in
sub G1, G0/G1, S, and G2/M phases, so as to determine how each
subpopulation contributes to the observed effects of the drugs, as
single agents or combined.
Cell cycle models have been developed previously to
characterize cell cycle arrest and induction of apoptosis for drugs
such as gemcitabine (Jusko, 1973; Hamed et al., 2013; Zhu et al.,
2015). In this study, we extended a cell cycle model (Hamed
et al., 2013) to integrate components of our previous model
(Miao et al., 2016a) in order to characterize cell cycle effects of
drug combinations. We measured cell proliferation as temporal
changes in total cell numbers, as well as the fraction of cells in
each phase of the cell cycle, and used the absolute cell number
in each cell cycle phase as a PD endpoint for model fitting and
qualification. The cell cycle models feature the dimensions of
time, drug concentration, and drug effects on cell subpopulations.
The application of mathematical modeling of cell subpopulation
responses to combination therapy, and gaining an understanding
of drug effects upon the transition rates between cell cycle
phases, provides a greater insight into the molecular
mechanisms underlying the synergistic effects of gemcitabine and
trabectedin.
MATERIALS AND METHODS
Reagents
Gemcitabine hydrochloride was purchased from Eli Lilly
(Indianapolis, IN), dissolved in sterile double-distilled water,
and stored at −20◦C at a stock concentration of 50 mM.
Trabectedin, obtained as a gift from PharmaMar (Madrid, Spain),
was prepared as a 1 mM stock solution in dimethylsulfoxide
(DMSO) and stored at−20◦C.
Cell Culture
The pancreatic cancer cell lines MiaPaCa-2 and BxPC-3 were
purchased from American Type Culture Collection (ATCC).
MiaPaCa-2 cells were grown in DMEM (Cellgro, Manassa, VA)
supplemented with 10% (v/v) fetal bovine serum (Cellgro).
BxPC-3 cells were cultured in RPMI (Cellgro), 10% (v/v) fetal
bovine serum and 1% (v/v) sodium pyruvate (Gibco, Grand
Island, NY). Cells were maintained in 5% CO2 at 37
◦C with 95%
humidity and grown as monolayers in T75 tissue culture flasks
(BD Biosciences, Bedford, MA).
Cell Proliferation Assay
To enable exponential cell growth for the duration of the
experiment, 1.5 − 2 × 106 cells in 5mL fresh medium were
seeded in 6-well plates and allowed to adhere overnight. Cells
then were treated in triplicate with 4 different concentrations of
gemcitabine and trabectedin, alone or combined, for 6 different
time intervals of up to 120 h (Table 1). Equivalent volumes of
water or DMSO were added as vehicle controls for the two drugs.
At the appropriate times, triplicate wells of cells were washed
twice with Dulbecco’s phosphate buffered saline (Gibco) and
suspended by incubating in 500mL 1×Trypsin EDTA (Cellgro)
for 5min. Cells were counted using a Coulter Counter model Z2
(Beckman Coulter, Hialeah, FL), and analyzed by flow cytometry.
Cell Cycle Assay
Aliquots of the cell suspensions were fixed in 70% cold ethanol
(Decan Laboratories, King of Prussia, PA) and stored at −20◦C
until flow cytometry analysis, which was performed within 2
weeks. In brief, the ethanol was removed and cells were washed
in cold Stain Buffer (BD Pharmingen, San Diego, CA) and treated
for 30min at room temperature in the dark with propidium
iodide (PI) containing RNase (BD Pharmingen). Based upon
analysis of the DNA content of each cell, histograms of cell
distribution in the different cell cycle phases were obtained using
TABLE 1 | Concentrations of gemcitabine (G) and trabectedin (T) tested as
single agents and in combination in cell culture studies.
Cell line Drug Concentration (nM)
MiaPaCa-2 Gemcitabine (G) 0, 15, 23, 45
Trabectedin (T) 0, 0.8, 1, 1.5
Combinations 15G+0.8T, 23G+0.8T, 23G+1T, 45G+1T
BxPC-3 Gemcitabine (G) 0, 11, 17, 34
Trabectedin (T) 0, 0.5, 0.7, 1.1
Combinations 11G+0.5T, 17G+0.5T, 17G+0.7T, 34G+1.1T
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a FACSort flow cytometer (Becton Dickinson, San Jose, CA). The
CellQuest,WinList, andModFit LT 4.0 software (Verity Software,
Topsham, ME) were used for analysis of cell cycle distribution
and determination of the fraction of cells in the G0/G1, S, and
G2/M phases. Apoptosis was measured by quantifying the sub G1
peak. Measurement accuracy was evaluated from the coefficient
of variation (CV%). Each sample was assayed in triplicate.
The number of cells in each cell cycle phase was obtained by
multiplying the total cell numbers of each sample by the fraction
of cells in each phase.
Mathematical Model
The models were premised on known cell cycle processes with
components informed by observations of perturbations caused
by the drugs. Mathematical models (Figure 1) were developed
based on a series of ordinary differential equations using a step-
wise modeling approach to characterize the experimental data.
In the first step, the cell cycle base model was constructed
with saturation of cell numbers and contact inhibition of cell
proliferation included to describe the vehicle control data. In
the second step, the cell cycle base model was extended to
include estimates of the cytostatic and cytotoxic effects of the
single drugs. Model components for drug- and cell line-specific
behaviors over time and concentration were included. Finally, the
cell cycle models of gemcitabine and trabectedin were combined,
and combination drug effects were incorporated in the model.
Parameters estimated from previous steps were fixed when
performing model fitting in the subsequent steps.
Cell Cycle Base Model
A cell cycle base model (Figure 1A; Hamed and Roth, 2011;
Hamed et al., 2013) was used previously to characterize the time
course of three cell cycle phases in the absence of drug:
dG1
dt
= 2k3G2 − k1G1 G1(0) = G
0
1 (1)
dS
dt
= k1G1 − k2S S(0) = S
0 (2)
dG2
dt
= k2S − k3G2 G2(0) = G
0
2 (3)
Rtot = G1 + S + G2 (4)
where G1 is the number of cells in G0/G1 phase, S is the cell
number in S phase, and G2 are cells in G2/M phase. In our
study, neither G0 and G1 nor G2 and M were distinguishable
experimentally. The total cell number is Rtot and the first-order
transition rates among the consecutive phases are k1, k2 and
k3. Equations (1)–(3) are a linear system and all phases have
exponential behavior without saturation. The doubling time can
be approximated by Td = 1/k1 + 1/k2 + 1/k3.
Saturation of total cell growth toward a maximal cell count at
steady-state Rss was introduced by slowing the doubling process
in Equation (1) via:
dG1
dt
= 2 k3G2
(
1−
R tot
2R ss
)
− k1G1 G1(0) = G
0
1 (5)
with this modification Td holds only for early times. Please note
that multiplication of Rss by 2 is necessary to adjust for the
doubling factor at G2, see Appendix for details.
To account for cell contact inhibition, the outflow fromG0/G1
was modified by slowing the transition rate k1. The final cell cycle
model (Figure 1B) without drug effects is then:
dG1
dt
= 2 k3G2
(
1−
Rtot
2Rss
)
− k1
(
1−
Imaxt
γ
IT
γ
50+ t
γ
)
G1
G1(0) = G
0
1 (6)
dS
dt
= k1
(
1−
Imaxt
γ
IT
γ
50+ t
γ
)
G1 − k2S S(0) = S
0 (7)
dG2
dt
= k2S − k3G2 G2(0) = G
0
2 (8)
Rtot = G1+ S + G2 (9)
where Imax is the maximal growth inhibition effect of cell contact,
IT50 is the time when the half-maximal inhibition effect is
achieved, and γ is the Hill coefficient. For increasing times, the
states of the three cell phases in Equations (6)–(9) converge
toward:
G∗1 =
Rss
1 + k1
k2
(1− Imax) +
k1
k3
( 1− Imax)
, (10)
S∗ =
k1
k2
( 1− Imax)G
∗
1 and G
∗
2 =
k1
k3
(1− Imax)G
∗
1 . (11)
The Appendix provides derivations of Equations (10) and (11).
Cell Cycle Model of Gemcitabine and
Trabectedin As Single Agents
Gemcitabine and trabectedin have concentration- and time-
dependent effects on the transition rates. In addition, the
MiaPaCa-2 and BxPC-3 cell lines showed different behaviors,
and appropriate model adjustments were necessary for these
factors. To avoid repetitive representation of the specific model
equations, we present a general model structure and list only the
necessary adjustments for the different drugs and cell lines. The
general model is:
dG1
dt
= 2k3eZ,3(CGem,CTbd)G2(1−
Rtot
2Rss
) G1(0) = G
0
1
− k1eZ,1(CGem,CTbd)(1−
Imaxt
γ
IT
γ
50+ t
γ
)G1 (12)
− aGem(i
Gem
G1 )G1 − aTbd(i
Tbd
G1 )G1
dS
dt
= k1eZ,1(CGem,CTbd)(1−
Imaxt
γ
IT
γ
50+ t
γ
)G1 S(0) = S
0
− k2eZ,2(CGem,CTbd)S (13)
− aGem(i
Gem
S )S− aTbd(i
Tbd
S )S
dG2
dt
= k2eZ,2(CGem,CTbd)S− k3eZ,3(CGem,CTbd)G2 (14)
G2(0) = G
0
2
− aGem(i
Gem
G2 )G2 − aTbd(i
Tbd
G2 )G2
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FIGURE 1 | Schematic of the pharmacodynamic models for single and combination drug effects on the cell cycle. (A) Cell cycle base model. (B) Alternative
cell cycle base model. (C) Cell cycle model of gemcitabine for MiaPaCa-2 cells. (D) Cell cycle model of gemcitabine for BxPC-3 cells. (E) Cell cycle model of
trabectedin for MiaPaCa-2 and BxPC-3 cells. (F) Cell cycle model of drug combination for MiaPaCa-2 cells. (G) Cell cycle model of drug combination for BxPC-3 cells.
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dA
dt
= aGem(i
Gem
G1 )G1+ aTbd(i
Tbd
G1 )G1+ aGem(i
Gem
S )S (15)
+ aTbd(i
Tbd
S )S + aGem(i
Gem
G2 )G2+ aTbd(i
Tbd
G2 )G2
−kapopA A(0) = 0
Rtot = G1+ S+G2+A (16)
where CGem and CTbd are the concentrations of gemcitabine
and trabectedin, A is the cell number in the sub G1 phase, and
kapop is the first-order rate constant for apoptosis. Drug and
cell-line effects on the transition rates are modeled by the effect
functions eZ,1, eZ,2, and eZ,3 for gemcitabine and trabectedin,
where Z denotes either the MiaPaCa-2 (M) or BxPC-3 (B) cell
line. Apoptotic drug effects are described by on/off functions of
the form:
aX(i) =
{
K 4,X if i = 1
0 if i = 0
(17)
where i = 1 indicates that a delayed apoptotic effect occurs as
described by:
KX =
Kmax,XC
γX
X
KC
γX
50,X + C
γX
X
(18)
dK1,X
dt
=
1
τX
(KX−K1,X) K1,X(0)= 0 (19)
dKj,X
dt
=
1
τX
(Kj− 1,X−Kj,X) Kj,X(0) = 0 j = 2, . . . , 4 (20)
where KX represents the non-linear cytotoxicity function, Kj,X
are transit steps, Kmax,X is the maximum killing rate, KC50,X is
the sensitivity constant, and γX is the Hill coefficient. X indicates
eitherGem or Tbd. If no apoptotic effect exists, i = 0 in Equation
(17). Four transit steps were previously found (Miao et al., 2016a)
optimal to describe the time delay.
Gemcitabine
The general cell cycle models structure described above was
refined to characterize gemcitabine effects on MiaPaCa-2
(Figure 1C) and BxPC-3 (Figure 1D) cells. Gemcitabine-induced
cell cycle arrest was modeled as inhibition of the transition rate
between S and G2/M phase. It was assumed that gemcitabine
induced apoptosis from S phase for MiaPaCa-2 cells and both
G0/G1, and S phases for BxPC-3 cells. This accounts for the
greater sensitivity of BxPC-3 cells to gemcitabine compared to
MiaPaCa-2 cells (Miao et al., 2016a).
Model Equations for Gemcitabine on MiaPaCa-2
Cells
The transition rate k1 increases with gemcitabine concentrations
as described by:
eM,1(CGem, 0) = exp(αk1(CGem−Cref )) (21)
where αk1 is a rate constant, and Cref is a reference
concentration. In this study, Cref is always set to the
lowest gemcitabine concentration in all subsequent terms.
As a result, k1 will increase exponentially with increasing
gemcitabine concentrations. Gemcitabine-induced cell cycle
arrest in S phase is modeled by inhibition of transition rate k2
with:
eM,2(CGem, 0)
=
(
1−
Imax,Gem(1− exp(− k(CGem−Cref )))C
γGem1
Gem
IC
γGem1
50,Gem+C
γGem1
Gem
)
(22)
where Imax,Gem represents gemcitabine maximum inhibition in S
phase, IC50,Gem is the gemcitabine concentration inducing 50%
of cell cycle arrest, and γGem1 is the Hill coefficient. Of note,
the cell cycle arrest in S phase is concentration-dependent, and
thus an exponential term with rate of k is used to describe
increased inhibition as gemcitabine concentrations increase.
Cref is always set to the lowest gemcitabine concentration.
The Cref was used for gemcitabine not for trabectedin. This
is because the concentration-response curve for gemcitabine is
more gradual compared to trabectedin, and the gemcitabine
concentrations were chosen at about 0, 12 IC50, IC50 and 2IC50
values for both cell lines, thus the concentration-dependency
is more prominent at high concentrations for gemcitabine.
For trabectedin, the concentration-response curve is steeper, so
the concentration-dependency is more prominent and there is
no need to incorporate Cref . The exponential term has values
between 0 and 1. The transition rate k3 is not affected by time
and concentration, and we set:
eM,3 (CGem, 0) = 1. (23)
Apoptotic effects are assumed to occur in the S phase only, and
therefore we have iGemG1 = i
Gem
G2 = 0, i
Gem
S = 1 and i
Tbd
G1 =
iTbdS = i
Tbd
G2 = 0. The overall model utilizes Equations (12)–
(20) with Equations (21)–(23), and the schematic is depicted in
Figure 1C.
Model Equations for Gemcitabine on BxPC-3 Cells
No effect of gemcitabine was observed on k1 and we set
eB,1 (CGem, 0) = 1. (24)
For early time points all drug-exposed cells are arrested in
S phase. But this effect wanes with longer exposure times.
Therefore, Equation (22) is extended by an exponential term, and
the time- and concentration-dependent effect of gemcitabine on
k2 is given by:
eB,2(CGem, 0) = (1− exp(−αk2t))(
1−
Imax,Gem(1− exp(− k(CGem−Cref )))C
γGem1
Gem
IC
γGem1
50,Gem + C
γGem1
Gem
)
. (25)
The exponential term was applied to k2 to describe k2 increases
with rate constant αk2. This is based on the assumption that
gemcitabine perturbs k2 by changing cell cycle regulation such as
cyclin-CDK protein expression over time (Yip-Schneider et al.,
2001).
In addition, we assume that k3 increases as gemcitabine
concentrations increase, as described by:
eB,3 (CGem, 0) = exp
(
αk3
(
CGem−Cref
))
. (26)
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Apoptosis occurs in the G1 and S phases, and we set
iGemG1 = i
Gem
S = 1, i
Gem
G2 = 0 and i
Tbd
G1 = i
Tbd
S = i
Tbd
G2 = 0.
The overall model includes Equations (12)–(20) with Equations
(24)–(26). The schematic is depicted in Figure 1D.
Trabectedin
Trabectedin-induced cell cycle arrest was modeled as inhibition
of the transition from S to G2/M phases and from G2/M to
G0/G1 phases, and cells in all cycle phases may commit to
apoptosis. A diagram of the cell cycle model for trabectedin is
shown in Figure 1E.
Model Equations for Trabectedin on MiaPaCa-2 Cells
The transition rate k1 increases with increasing trabectedin
concentration by:
eM,1 (0,CTbd) = exp (βk1CTbd) . (27)
The transition rate k2 increases over time by:
eM, 2 (0, CTbd) =
(
1 −
Imax,Tbd, S exp
(
− kSt
)
C
γTbd1
Tbd
IC
γTbd1
50,Tbd, S
+ C
γTbd1
Tbd
)
(28)
whereas k3 is inhibited over time:
eM, 3 (0, CTbd) =
(
1−
Imax,Tbd,G2
(
1− exp
(
− kG2t
))
C
γTbd2
Tbd
IC
γTbd2
50,Tbd,G2
+ C
γTbd2
Tbd
)
.
(29)
Additionally, apoptosis can initiate in all phases by setting
iTbdG1 = i
Tbd
S = i
Tbd
G2 = 1 and i
Gem
G1 = i
Gem
S = i
Gem
G2 = 0.
The overall model entails Equations (12)–(20) with Equations
(27)–(29).
Model Equations for Trabectedin on BxPC-3 Cells
Transition rates k1 and k2 were modeled with Equations (27)
and (28). We assumed that the inhibition of transition rate k3
increases over time and k3 exhibits concentration-dependency:
eB, 3(0, CTbd) =
(
1−
Imax,Tbd,G2
(
1− exp
(
−kG2t
))
C
γTbd2
Tbd
IC
γTbd2
50,Tbd,G2
+ C
γTbd2
Tbd
)
exp (βk3CTbd). (30)
Apoptosis can initiate in all phases, described by iTbdG1 = i
Tbd
S =
iTbdG2 = 1 and i
Gem
G1 = i
Gem
S = i
Gem
G2 = 0. The overall model
includes Equations (12)–(20) with Equations (27), (28), and (30).
Cell Cycle Model of Drug Combinations
The time- and concentration-dependent drug effects of
gemcitabine and trabectedin as single agents on k1 and k3 are
multiplied for the drug combination. Both drugs interact at
the transition from S to G2/M phase and at the induction of
apoptosis. Instead of multiplying the single effects, we assume
competitive drug interactions for cell cycle arrest in S phase
and apply the competitive combination effect term from Ariëns
et al. (Ariens et al., 1957; Koch et al., 2016). For the induction of
apoptosis, the effects of both cytotoxic drug effects are summed
(Miao et al., 2016a). To account for remaining interaction effects
not predicted by the model, two interaction parameters, ψ1
and ψ2 (Chakraborty and Jusko, 2002; Koch et al., 2009) were
included at the points where the drugs interact on cell cycle
inhibition and induction of apoptosis. If ψ1 or ψ2 equals 1,
the effect of the combination is additive, based on the applied
combination effect term. A ψ1 or ψ2 value smaller than 1
indicates synergistic interaction, and any value greater than 1
indicates antagonistic combination behavior.
Model Equations for Combinations on MiaPaCa-2
Cells
The drug interaction on k1 was modeled with multiplication of
single drug effects. For k1 we obtain:
eM,1(CGem,CTbd) = exp
(
αk1(CGem−Cref )
)
exp (βk1CTbd).
(31)
Because both gemcitabine and trabectedin act on the transition
from S to G2/M, we assumed a competitive behavior and
multiplied the interaction parameter ψ1 by the IC50 of
gemcitabine:
E (CGem,CTbd) =

1− Imax,Gem
(
1− exp
(
− k
(
CGem−Cref
))) ( CGem
ψ1IC50,Gem
)γGem1
+ Imax,Tbd,S exp
(
− kSt
)( CTbd
IC50,Tbd,S
)γTbd1
1+
(
CGem
ψ1IC50,Gem
)γGem1
+
(
CTbd
IC50,Tbd,S
)γTbd1

 (32)
and set
eM,2 (CGem,CTbd) = E (CGem,CTbd) . (33)
In Equation (18),ψ2 is multiplied by theKC50,Gem of gemcitabine.
Because gemcitabine has no effect on k3, (compare Equation 23),
the final equations for the combination model are Equations
(12)–(20) with Equations (29), (31)–(33) where we set iGemG1 =
iGemG2 = 0, i
Gem
S = 1 and i
Tbd
G1 = i
Tbd
S = i
Tbd
G2 = 1.
Model Equations for Combinations on BxPC-3 Cells
For k1 we apply Equation (27). The transit rate k2 is influenced
by the competitive effect Equations (32) and a time-dependent
effect, (compare Equation 25):
eB,2 (CGem,CTbd) =
(
1 − exp (−αk2t )
)
E (CGem,CTbd) . (34)
For k3:
eB,3 (CGem,CTbd)
=
(
1−
Imax,Tbd,G2
(
1− exp
(
−kG2t
))
C
γTbd2
Tbd
IC
γTbd2
50,Tbd,G2
+ C
γTbd2
Tbd
)
exp
(
αk3(CGem − Cref )
)
exp (βk3CTbd). (35)
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The model equations are Equations (12)–(20) with Equations
(27), (32), (34), (35) and iGemG1 = i
Gem
S = 1, i
Gem
G2 = 0, i
Tbd
G1 =
iTbdS = i
Tbd
G2 = 1.
Data Analysis
The modeling was performed using ADAPT 5 software
(D’Argenio et al., 2009) with a naive pooled approach. Models
were fitted to the data using the maximum likelihood (ML)
estimation method. The variance model was:
Vi = (σ1 + σ2Yi)
2 (36)
where Vi is the variance of the ith time point, σ1 and σ2 are
variancemodel parameters, andYi is the predicted response at ith
time point. The goodness of fit was assessed by visual inspection
of model fittings, goodness-of-fit plots, the Akaike Information
Criteria (AIC), and the coefficients of variation (CV %).
RESULTS
Cell Cycle without Perturbation (Baseline
Model)
Figure 2 shows the cell cycle distribution of MiaPaCa-2
(Figures 2A,B) and BxPC-3 cells (Figures 2C,D) in the absence
of drug. Both cell lines showed progressive accumulation in the
G0/G1 phase with time (Figures 2A,C). Numerous factors can
cause accumulation of the cell population in the G0/G1 phase.
Serum starvation, a reduction in nutrients, or contact inhibition
as a result of increasing cell confluence activate cell growth
checkpoints and cell cycle arrest occurs at the G0/G1 phase
(Hayes et al., 2005; Choresca et al., 2009; Dalman et al., 2010).
Total cell numbers and the number of cells in different
cycle phases, were modeled simultaneously with the cell cycle
base model (Figure 1B). The model was able to characterize
well the observed data (Figures 2B,D). Parameter estimates are
shown in Table 2. These model estimates were then fixed for
subsequent analyses. The approximate doubling time Td for
MiaPaCa-2 was 31.9 and 16.8 h for BxPC-3 cells. Cells finally
reached a steady-state Rss, which was 6.00 × 10
6 cells (fixed to
a value observed in the study, data not shown) for MiaPaCa-2
and 7.98 × 105 cells for BxPC-3 cells. Under the experimental
conditions used here, the time to reach half of the maximal
cell contact inhibition was 45.4 h for MiaPaCa-2 and 61.0 h for
BxPC-3 cells.
Gemcitabine Effects upon Cell Cycle and
Model Prediction
Figure 3 shows the effects of gemcitabine on the cell cycle
distribution of MiaPaCa-2 (Figures 3A–C) and BxPC-3 cells
(Figures 3D–F). As time increased, 45 nM gemcitabine induced
S phase accumulation of MiaPaCa-2 cells (Figure 3A and
Supplemental Table 1). A gradual increase of cells in S
phase also was observed after exposure of BxPC-3 cells to
34 nM gemcitabine (Figure 3D and Supplemental Table 1).
Gemcitabine-induced S phase cell cycle arrest was concentration-
dependent for both MiaPaCa-2 (Figure 3B) and BxPC-3
cells (Figure 3E). Apoptosis, measured as the percentage of
FIGURE 2 | Cell cycle phase distributions in the vehicle control groups for MiaPaCa-2 and BxPC-3 cells. (A,C) Percent of cells in G0/G1, S, and G2/M
phases at 0, 24, 48, 72, and 96 h (MiaPaCa-2) and 0, 16, 26, 48, 72, and 96 h (BxPC-3) for vehicle control groups. Columns, mean of triplicate; bars, SD. N = 3.
(B,D) Data and model fitting of vehicle control groups. Numbers of cells in G0/G1, S, and G2/M phases, as well as total cells over time, are represented by symbols.
Model fittings based on the model of Figure 1B are indicated by lines.
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TABLE 2 | Pharmacodynamic model parameter estimates for two cell lines. Parameters were obtained after fitting to the cell cycle base model shown in
Figure 1B.
Cell Line Definition Units MiaPaCa-2 BxPC-3
Parameters Estimate (CV%) Estimate (CV%)
k1 Transition rate between G0/G1 and S phase h
−1 0.0693 (7.92) 0.166 (6.58)
k2 Transition rate between S and G2/M phase h
−1 0.101 (4.11) 0.149 (5.43)
k3 Transition rate between G2/M and G0/G1 phase h
−1 0.132 (3.99) 0.245 (5.78)
G01 Initial cell number at G0/G1 phase cells× 10
3 159 (5.30) 91.6 (4.60)
S0 Initial cell number at S phase cells× 103 111 (5.55) 73.5 (4.75)
G02 Initial cell number at G2/M phase cells× 10
3 64.9 (5.83) 30.2 (5.04)
Rss Cell number at steady-state cells× 10
3 6000a 798 (2.75)
Imax Maximum inhibition on k1 0.922 (1.80) 0.868 (22.8)
IT50 Time inducing 50% of maximum inhibition Imax h 45.4 (6.31) 61.0 (14.4)
γ Hill coefficient 4.37 (16.9) 3.30 (43.8)
aThe value is fixed.
sub-diploid cells, appeared at the highest-tested gemcitabine
concentrations for both cell lines.
Based upon mechanisms of gemcitabine effects on the cell
cycle, mathematical models were developed for MiaPaCa-2
(Figure 1C) and BxPC-3 cells (Figure 1D). Figures 3C,F show
the model fittings. In general, the model well captured the
trend of the observed data. Considering the large number and
complexities of the datasets, model performance is acceptable.
Table 3 shows parameter estimates for the drugs as single agents.
Gemcitabine-induced S phase arrest was modeled as inhibition
of the transition rate from S to G2/M phase. The maximum
inhibition Imax,Gem was fixed to 1 for both cell lines. The
concentrations that induced half-maximal S phase arrest IC50,Gem
were 11.5nM for MiaPaCa-2 and 48.1 nM for BxPC-3. Because
the maximal inhibition Imax,Gem was concentration-dependent,
inhibition increased proportional to the rate constant k, which
was 0.0281 nM−1 for MiaPaCa-2 and 1 nM−1 for BxPC-3
cells. The model assumed that gemcitabine-induced apoptosis
occurred in S phase in MiaPaCa-2 cells, and in both G0/G1 and S
phases in BxPC-3 cells, and the parameters related to gemcitabine
killing effects were fixed to parameters derived in our previous
study (Miao et al., 2016a). Minor differences between MiaPaCa-
2 and BxPC-3 cells also included certain model assumptions;
for MiaPaCa-2, it was assumed that k1 increased with rate of
αk1 (0.0612 nM
−1) with increased gemcitabine concentrations.
For BxPC-3, it was assumed that k2 and k3 increased with
rates of αk2 (0.0635 h
−1) and αk3(0.0605 nM
−1) as gemcitabine
concentrations increased.
Trabectedin Effects upon Cell Cycle and
Model Prediction
Figure 4 shows the effects of trabectedin on the cell cycle
distribution for MiaPaCa- 2 (Figures 4A–C) and BxPC-3 cells
(Figures 4D–F). For both cell lines, trabectedin induced cell cycle
arrest at S phase at early time points, followed by progression
to G2/M phase at later time points. Figure 4A shows the cell
cycle distribution of MiaPaCa-2 cells after exposure to 0.8 nM
trabectedin for 0, 24, 48, 72, and 96 h. At 24 h, cell cycle arrest
occurred in the S phase (Supplemental Table 1). Similar effects
were observed in BxPC-3 cells (Figure 4D and Supplemental
Table 1). Trabectedin effects on the cell cycle were concentration-
dependent (Figures 4B,E), for both cell lines at early time points,
and S phase accumulation increased with concentration. As
exposure times increased (48–76 h) the accumulation shifted
from S to G2/M phase.
Based upon the mechanistic effects of trabectedin on the
cell cycle, mathematical models were developed (Figure 1E).
Trabectedin effects on cell cycle checkpoints were modeled
with inhibition effects on both S to G2/M phase transition
k2 and the G2/M to G0/G1 phase transition k3. In order to
characterize early S phase arrest followed by subsequent G2/M
phase arrest, models were constructed in such a way that S
phase inhibition decreased with time with rate kS and inhibition
in G2/M phase increased with time with rate kG2. The kS was
1 h−1 for MiaPaCa-2 and 0.00204 h−1 for BxPC-3, whereas
kG2 was 0.0270 h
−1 for MiaPaCa-2 and 0.0516 h−1 for BxPC-3
cells. Trabectedin concentrations inducing half-maximal S phase
inhibition (IC50,Tbd,S) were 0.222 nM for MiaPaCa-2 and 1.03
nM for BxPC-3 cells. Concentrations inducing half-maximal
G2/M phase inhibition (IC50,Tbd,G2) were 0.525 nM forMiaPaCa-
2 and 0.681 nM for BxPC-3 cells, suggesting that MiaPaCa-2 cells
are also more sensitive to trabectedin-inducedG2/M phase arrest
than BxPC-3 cells. In addition, we also assumed concentration-
dependent trabectedin effects on k1, with rates of βk1 of 2.64
nM−1 for MiaPaCa-2 and 0.637 nM−1 for BxPC-3. For BxPC-
3, k3 also increased with trabectedin concentration, with a rate of
βk3 of 0.296 nM
−1. Finally, trabectedin-induced apoptosis was
assumed to occur in all cell cycle phases. For both cell lines,
the parameters related to trabectedin killing effects were fixed to
values obtained previously (Miao et al., 2016a).
Modeling Combined Drug Effects upon
Cell Cycle
Analysis of experimental data suggested that trabectedin and
gemcitabine exert different effects upon cell cycle progression.
For both cell lines, gemcitabine induced cell cycle arrest in
S phase (Figure 3), but with trabectedin a population of cells
passed through S phase and accumulated in G2/M phase cells
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FIGURE 3 | Gemcitabine effects on the cell cycle for MiaPaCa-2 and BxPC-3 cells. (A,D) Histograms showing temporal changes in cellular DNA content after
incubation with 45 nM gemcitabine in MiaPaCa-2 cells and 34 nM in BxPC-3 cells. All data are in triplicate. (B,E) fraction of cells in subG1, G0/G1, S, and G2/M
phases after incubating cells with concentrations of gemcitabine shown for 48 (MiaPaCa-2) or 76 (BxPC-3) h. Columns, mean of triplicate determinations; bars, SD.
(C,F) Data and model fitting results of cells incubating cells with concentrations of gemcitabine shown for up to 120 h. Symbols represent data for cells numbers in
G0/G1, S, G2/M, subG1 phase as well as total cell numbers; lines show model fittings based on PD models in Figure 1C (MiaPaCa-2) and Figure 1D (BxPC-3).
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TABLE 3 | Pharmacodynamic model parameter estimates. Parameters were obtained after fitting to cell cycle models for either gemcitabine
(Figures 1C,D) or trabectedin (Figure 1E) as single agents.
Cell line Definition Units MiaPaCa-2 BxPC-3
Parameters Estimate (CV%) Estimate (CV%)
kapop Elimination rate from apoptosis compartment h
−1 0.0815 (8.71) 3.33 (17.4)
Imax,Gem Maximum inhibition of k2 1
a 1a
IC50,Gem Gemcitabine concentration inducing 50% of Imax, Gem nM 11.5 (264) 48.1 (12.6)
γGem1 Hill coefficient for gemcitabine effects on cell cycle arrest at S phase 5
a 5a
k Rate constant increasing Imax,Gem with gemcitabine concentration nM
−1 0.0281 (7.47) 1a
αk1 Rate constant k1 increases with gemcitabine concentration nM
−1 0.0612 (6.10)
αk2 Rate constant k2 increases with time h
−1 0.0635 (13.7)
αk3 Rate constant k3 increases with gemcitabine concentration nM
−1 0.0605 (8.21)
Imax,Tbd,S Trabectedin maximum inhibition at S phase arrest 1
a 1a
IC50,Tbd,S Trabectedin concentration inducing 50% of Imax, Tbd,S nM 0.222 (>100) 1.03 (4.57)
γTbd1 Hill coefficient for trabectedin effects at S phase arrest 5
a 5a
Imax,Tbd,G2 Trabectedin maxium inhibition at G2/M phase arrest 1
a 1a
IC50,Tbd,G2 Trabectedin concentration inducing 50% of Imax,Tbd,G2 nM 0.525 (5.87) 0.681 (5.64)
γTbd2 Hill coefficient for trabectedin effects at G2/M phase arrest 5
a 5a
kS Rate constant Imax,Tbd,S decreases with time h
−1 1a 0.00204 (135)
kG2 Rate constant Imax,Tbd, G2 increases with time h
−1 0.0270 (4.32) 0.0516 (21.1)
βk1 Rate constant k1 increases with trabectedin concentration nM
−1 2.64 (2.60) 0.637 (12.1)
βk3 Rate constant k3 increases with trabectedin concentration nM
−1 0.296 (66.3)
Kmax,Gem Maximal cell kill constant for gemcitabine h
−1 0.166b 0.0613b
KC50,Gem Gemcitabine concentration inducing 50% of Kmax,Gem nM 41.5
b 21.4b
1/τGem Transit constant for gemcitabine h
−1 0.0370 (4.00) 0.0671b
γGem Hill coefficient for gemcitabine 0.527 (44.5) 2.08
b
Kmax,Tbd Maximal cell kill constant for trabectedin h
−1 0.0858b 0.261b
KC50,Tbd Trabectedin concentration inducing 50% of Kmax−Et743 nM 1.63
b 6.31b
1/τTbd Transit constant for trabectedin h
−1 0.0569 (4.31) 0.0452b
gammaTbd Hill coefficient for trabectedin 2.43 (9.26) 1.07
b
aThe value is fixed.
bThe value is fixed to parameter estimates from Table 3 in Miao et al. (2016a).
(Figure 4). In order to model combined drug effects upon
the cell cycle, the PD models for the single agents were
integrated (Figures 1F,G) and used to fit simultaneously the
data for four different drug concentration combinations on
MiaPaCa-2 (Figure 5A) and BxPC-3 cells (Figure 5B). Figure 5C
shows the BxPC-3 cell growth model fitting of experimental
data for BxPC-3 cells. The model captured the trend of the
data well.
Table 4 provides parameter estimates and statistics for
the combined drugs. For both cell lines, a competitive
interaction equation was used to model S phase inhibition
by the two drugs. The interaction term ψ1 was multiplied
at IC50,Gem. The ψ1 interaction parameter was fixed to 1
for MiaPaCa-2 cells (because modeling of ψ1 for S phase
inhibition resulted in a value of about 1) and estimated as
0.975 for BxPC-3 cells, suggesting additive drug interaction
on S phase inhibition. The ψ2 was multiplied by KC50,Gem
to characterize drug interactions for induction of apoptosis.
Estimates of ψ2 were 0.499 for MiaPaCa-2 cells and 0.363
for BxPC-3 cells, indicating synergistic interactions in inducing
apoptosis.
DISCUSSION
Mathematical models serve to help integrate information from
complex studies, assess mechanisms of drug interactions, and
guide selection and optimization of drug combinations. We
previously introduced a mathematical framework based on a
semi mechanism-based approach to model gemcitabine and
trabectedin combination effects on pancreatic cancer cells (Miao
et al., 2016a). That simple and reasonable approach could be
applied to other drugs, and could also be useful to characterize
time- and concentration-dependent drug-drug interactions.
The present work goes beyond such semi-mechanistic
models. It incorporates cell subpopulation information and
enlarges the previous model in order to characterize drug
combination effects of gemcitabine and trabectedin on cell cycle
distribution.
Cancer cells are heterogeneous and asynchronous populations
are composed of cell subpopulations in different cycle phases
(Evan and Vousden, 2001). Drug sensitivity or mechanism may
vary for cells in different cycle phases. Cell cycle arrest at different
phases could influence cell sensitivity or resistance to drugs
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FIGURE 4 | Trabectedin effects on the cell cycle for MiaPaCa-2 and BxPC-3 cells. (A,D) histograms showing temporal changes in cellular DNA content after
continuous exposure of cells to 0.8 nM (MiaPaCa-2) or 1.1 nM (BxPC-3) trabectedin. All data are in triplicate. (B,E) Fraction of cells in sub G1, G0/G1, S, and G2/M
phase after incubating cells in the concentrations of trabectedin shown for 24, 48, and 72 h (MiaPaCa-2) or 26, 48, and 76 h (BxPC-3). Columns, mean of triplicate
determinations; bars, SD. (C,F) Temporal change in number of cells in G0/G1, S, G2/M, sub G1 phase, as well as total cell numbers, after incubating cells with
concentrations of trabectedin shown for up to 120 (MiaPaCa-2) and 96 h (BxPC-3). Symbols represent observed data and lines represent fitted curves generated
from PD model shown in Figure 1E.
significantly and affect overall responses to single or multiple
chemotherapeutic agents. To account for such drug effects, we
developed four cell cycle models: a cell cycle base model lacking
drug effects, cell cycle models for gemcitabine and trabectedin
as single agents, and a cell cycle model for drug combinations.
The models were applied to large experimental datasets that
captured relevant pharmacodynamic endpoints such as cell
proliferation, cell cycle phase, and induction of apoptosis. A
step-wise modeling approach was used, first fitting the control
(vehicle) data to the cell cycle base model (Figure 2), followed by
fitting single drug effects to the cell cycle models of gemcitabine
(Figure 3) and trabectedin (Figure 4). Ultimately, the combined
data were fitted with a cell cycle model of the drug combination
(Figure 5).
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FIGURE 5 | Drug combination effects and model-fittings based on individual drug mechanisms for MiaPaCa-2 and BxPC-3 cells. (A,B) Observed data
and model fitting results for cells exposed to different combinations of drug concentrations. Symbols represent cell numbers in G0/G1, S, G2/M, and sub G1 phases;
lines depict model fittings to the PD model shown in Figures 1F,G. (C) Shown are temporal cell proliferation profiles and model fitting results for single drug effects
and four different drug combinations for total BxPC-3 cells. Symbols represent experimental data and lines indicate the corresponding model fittings.
The total cell number was measured during drug exposure,
as was the fraction of cells in each cycle phase (G0/G1,
S, G2/M) and in apoptosis (sub G1). The developed model
incorporates not only changes in cell cycle distribution, but also
the dynamics of the whole cell population. The dataset was
large, consisting of ∼500 samples that each provided data for
5 cell populations, and was analyzed using ordinary differential
equations.
The proposed cell cycle model framework was developed
based on drug mechanisms observed in the study. For the
vehicle-treated controls, the data show that the G0/G1 fraction
increased with time, reflecting the fact that when cells reach
confluence, contact inhibition occurs, nutrients may become
limited, and a cell growth checkpoint is activated toward the
end of G1 phase. If cells are able to progress to S phase,
normal cycling occurs. Otherwise, cells enter a resting G0 phase
until they are able to resume cycling. For the vehicle control
group, the logistic growth function was used to characterize
saturation of total cells, while contact inhibition was used to
characterize G0/G1 phase cells increasing over time. The contact
inhibition was modeled with a time-dependent Hill function.
We have also tested contact inhibition with a feedback loop
where the inhibition of k1 is dependent on Rtot . However,
the time-dependent Hill type of equation was chosen as
it allows us to estimate the time where the half-maximal
effects of cell contact inhibition occurs and to simplify the
convergence analysis as presented in the Appendix. Our model
for gemcitabine was initially premised on that of Hamed et al.
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TABLE 4 | Pharmacodynamic interaction model parameter estimates.
Parameters Definition MiaPaCa-2 BxPC-3
Estimates (CV%)
95% CI
Estimates (CV%)
95%CI
ψ1 Interaction term for S
phase inhibition
1a 0.975 (35.9)
0.275–1.675
ψ2 Interaction term for
induction of apoptosis
0.499 (74.5)
0−1.243
0.363 (16.8)
0.241–0.485
aThe value is fixed.
Parameters were obtained after fitting to cell cycle models for combined drug interaction
effects (Figures 1F,G).
(2013), but more extensive measurements provided clearer
insights into drug effects on apoptosis. Further, for gemcitabine,
time- and concentration-dependent cell cycle arrest occurred
at the S phase, consistent with previous results (Yip-Schneider
et al., 2001; Morgan et al., 2005). The gemcitabine-induced S
phase arrest was modeled as both an increase in the transition
rate from G0/G1 and an inhibition of transition rates from
S phase to G2/M phase. The S phase arrest increased with
gemcitabine concentrations. Therefore, gemcitabine-induced cell
death is modeled with a non-linear killing function, with the
delay of killing effects modeled by four transit compartments.
Trabectedin induced cell cycle arrest in S phase at earlier time
points, but at later times, cells progressed through S to G2/M
phase. In order to capture the time-dependency, equations were
constructed such that an inhibition term on the transition from
S to G2/M decreased with time, and the inhibition term on the
transition from G2/M to G0/G1 increased with time. In addition,
we assumed that cells in all three cell cycle phases can commit to
apoptosis after drug treatment. The models employed a similar
basic structure for both MiaPaCa-2 and BxPC-3 cells, with only
minor changes required to reflect the unique characteristics of the
specific cell line. For example gemcitabine induced apoptosis in
S phase for MiaPaCa-2 cells, but apoptosis occurred in BxPC-3
cells in both S and G0/G1 phases. The models were constructed
with differences between cell lines. For example, based on the
KC50 of the two cell lines (Miao et al., 2016a), MiaPaCa-2 is
more trabectedin-sensitive while BxPC-3 is more gemcitabine-
sensitive. In addition, the two cells lines also have phenotypic
and genotypic differences; for example, MiaPaCa-2 has mutant
K-ras and p53 genes, whereas BxPC-3 has wild-type K-ras and
p53 genes (Deer et al., 2010). The final model permitted a
higher-resolution investigation of the basis of the synergistic
interaction of these drugs than previously (Miao et al., 2016a).
An interaction termψ was incorporated into specificmechanistic
model components to explore model behavior when interactions
in thosemechanisms were hypothesized to explain observed drug
effects of the combination that exceeded model predictions. In
the final developed model, ψ1 was applied to represent drug
interactions at the point of S phase arrest, and ψ2 was applied to
represent drug interactions at the point of induction of apoptosis.
However, ψ1 was approximately equal to 1, suggesting that drug
interactions in inducing S phase accumulation were additive,
whereasψ2 was<1, suggesting that drug interactions in inducing
apoptosis were synergistic.
Cell-cycle-specific compartmental models have been applied
previously for investigation of cancer chemotherapy agents.
Simple models can be constructed with as few as 4-5
compartments that represent each cycle phase (Kozusko et al.,
2001; Florian et al., 2005; Ribba et al., 2009). Compartments
can be added to represent apoptosis or other death mechanisms
(Basse et al., 2004; Panetta et al., 2006; Sherer et al., 2006; Zhu
et al., 2015), and additional components may be included to
account for more complex pharmacological mechanisms such
as cell cycle regulation (Senderowicz, 2004; Ferrell et al., 2011).
Most existing cell cycle models characterize single drug effects;
few reports model drug combinations (Gardner, 2002; Zhu
et al., 2015). Because of the layers of complexities in larger
and richer data sets, there is a need for models to account
for those complexities. The cell cycle models developed here
allow investigation of the specific effects of the individual
drugs in combination therapy upon cell cycle progression. For
example, we identified that gemcitabine exerts influence in the
S phase, whereas trabectedin exerts influence in both S and
G2/M phases. In addition, the models have the flexibility to
account for conditions under which drug effects upon specific
cycle phases or phase transitions are concentration- or time-
dependent. For example, the degree of gemcitabine-induced S
phase arrest increased with concentration. Finally, the developed
model was able to account for cell line differences; the two
cell lines investigated are different in phenotype and genotype
(Deer et al., 2010), and in their sensitivity to gemcitabine and
trabectedin (Miao et al., 2016a). Model development showed
that to capture differences in cell line–specific behaviors, drug
effects may be hypothesized to affect different, or even multiple
cycle phase transition rates, and apoptosis may be induced from
different cell cycle phases.
Traditional approaches to model tumor growth often include
a logistic or Gompertzian growth model. Such models are
empirical and do not take into account complex biological
mechanisms such as the cell cycle dynamics of subpopulations.
Here we used models based upon cell cycle structure to describe
cancer cell growth and drug effects. The final model characterized
very well not only cell cycle dynamics, but also cancer cell
proliferation (Figure 5C). The model can characterize cancer cell
growth without drug perturbation, and growth in response to
single- or combined cell-cycle-specific agents.
In conclusion, we have modeled chemotherapeutic drug
effects of single and combined agents on pancreatic cancer
cell cycle dynamics and apoptosis. The study suggests a
basis for the overall gemcitabine/trabectedin synergy observed
previously (Miao et al., 2016a) when examines cell cycle
subpopulations. The proposed model structure is not limited
to gemcitabine and trabectedin as single or combined agents,
and can be adapted to investigate efficacy of other cell-cycle
specific agents. Even though the cell cycle models developed
in this study are used to characterize in vitro data, the
model structures may be kept and integrated with more
model components accounting for cell and tissue heterogeneity
when translating to in vivo work. However, the mechanisms
underlying synergy within specific cell subpopulations remains
undefined at the level of protein- and pathway interactions.
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Further research, employing approaches such as high-resolution
proteomic investigation of drug action, may provide the means
to integrate information at that scale into the model structure
proposed here.
The model components and complications that were
introduced in this report for the dual drug effects on MiaPaCa-2
cells have been largely confirmed in our further studies that
utilized proteomic and western blot methods to assess drug
effects on various signaling pathways (Miao et al., 2016b).
The present report reflects the second part of our multi-
stage efforts to perform studies that employ modeling to
assess relevance of diverse physiologic and pharmacologic
processes and then employ more sophisticated methodology
to delve into possible and identified mechanisms and
complexities.
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APPENDIX
Behavior of Cell Cycle Model with
Saturation for Increasing Time
For t→∞ we obtain from Equations (6)–(8):
0 = 2k3G
∗
2
(
1−
G∗1 + S
∗ + G∗2
2Rss
)
− k1 (1− Imax)G
∗
1 (A1)
0 = k1 (1− Imax)G
∗
1 − k2S
∗ (A2)
0 = k2S
∗ − k3G
∗
2 . (A3)
From Equation (A3) one finds:
S∗ =
k3
k2
G∗2 . (A4)
From Equations (A2) and (A4) we have:
G∗2 =
k1 (1− Imax)
k3
G∗1 . (A5)
Hence, with Equation (A5) we obtain:
S∗ =
k1
k2
(1− Imax)G
∗
1 . (A6)
Substituting Equations (A5) and (A6) in (A1) results with b =
1− Imax in:
0 = 2k1bG
∗
1

1− G∗1
(
1+ k1
k2
b+ k1
k3
b
)
2Rss

− k1bG∗1 .
We set a = 1 + k1
k2
b + k1
k3
b, and cancel out the zero-solution to
obtain:
0 = 1−
G∗1a
Rss
⇔ G∗1 =
Rss
a
(A7)
yielding Equations (10) and (11). Summation of G∗1 , S
∗ and G∗2
from Equations (10) and (11) fulfills R∗tot = R
∗
ss.
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